You just read:

SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients

News provided by

SELLAS Life Sciences Group

Mar 01, 2017, 08:30 ET